We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

Vanguard Mid-CAP ETF offers a diversified option to invest in numerous mid-cap companies. Here's what investors should know.

Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

EST Cathie Wood’s ARK Investment buys 187K shares of Crispr Therapeutics (CRSP) todayMaximize Your Portfolio with Data Driven ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the March 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

ARK Invest's 13F portfolio value increased by ~10% to ~$12B this quarter. Check out the top holdings and new stakes of the ...